The SUSTAIN 6 cardiovascular outcomes trial, which followed patients for a median of 2.1 years, demonstrated a 26% reduction in the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke compared to placebo
The 2.5 mg dose is better called the low-dose starter, because it is the labeled start and now has short direct non-diabetic data behind it. Microdosing has been used for tolerability testing, metabolic-marker support, step-down protocols, and maintenance, not for proven long-term obesity outcomes
However, some people will experience a speeding up of their metabolism and a slight reduction in their weight
While using Semaglutide it is highly recommended that you: Eat a fibrous diet
Refer patients to structured education & weight management programmes Support patients to access structured education and weight management programmes where available
That means dosing schedules and handling differ from oral pills, and monitoring for immune reactions or altered clearance is part of clinical use